A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3 –1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer
Conclusions BTH1677 combined with cetuximab/carboplatin/paclitaxel was well tolerated and improved ORR as first-line treatment in patients with advanced NSCLC. Future patient selection by biomarker status may further improve efficacyClinicalTrials.gov Identifier: NCT00874848
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Drugs & Pharmacology | Erbitux | Investigational New Drugs | Lung Cancer | Non-Small Cell Lung Cancer | Radiology | Study